UCB reported a strong performance in its Q3 16 trading update (only top-line numbers). Sales were up by 12% yoy to €1.1bn (ahead of consensus), the outperformance primarily coming from Keppra, while CVN also performed fairly well (combined growth of 16%). Management confirmed full year guidance at the upper end of the range – revenue: €4-4.1bn, recurring EBITDA: €970-1,010m and core EPS of €2.9-3.2).
01 Nov 2016
No major surprises in Q3
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
No major surprises in Q3
UCB S.A. (UCB:WBO) | 0 0 1.1% | Mkt Cap: 13,141m
- Published:
01 Nov 2016 -
Author:
Jyoti Prakash -
Pages:
3
UCB reported a strong performance in its Q3 16 trading update (only top-line numbers). Sales were up by 12% yoy to €1.1bn (ahead of consensus), the outperformance primarily coming from Keppra, while CVN also performed fairly well (combined growth of 16%). Management confirmed full year guidance at the upper end of the range – revenue: €4-4.1bn, recurring EBITDA: €970-1,010m and core EPS of €2.9-3.2).